Fritz Reusser

This inventor holds 18 USPTO granted patents. Top assignees: The Upjohn Co., Pharmacia & Upjohn Company. Active years: 1976-1999.

USPTO Granted Patents = 18

% Patents Active = 100.0

Average Co-Inventor Count = 2.2

ph-index = 6

Forward Citations = 71(Granted Patents)

Company Filing History:

Pharmacia & Upjohn Company

patents

Years Active: 1976-1999

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5981537 - Pyrimidine-thioalkyl and alkylether compounds (1999-11-09),

2. 4749568 - Rubradirin treatment of methicillin-resistant staph (1988-06-07),

3. 4623644 - Acylation of tirandamycic, streptolic and sorbic acids to cephalosporin (1986-11-18),

4. 4540661 - Composition of matter and process (1985-09-10),

5. 4473649 - Antibiotic producing streptomyces (1984-09-25),

6. 4404190 - Composition of matter and process (1983-09-13),

7. 4397950 - Process for production of antibiotic U-64,767 using Streptomyces (1983-08-09),

8. 4362817 - Hybrid plasmid and process of making same (1982-12-07),

9. 4362816 - Hybrid plasmid and process of making same (1982-12-07),

10. 4343906 - Hybrid plasmid of pBR322 and Streptomyces plasmid and E. coli containing (1982-08-10),

11. 4332898 - Hybrid plasmid and process of making same (1982-06-01),

12. 4267112 - Antibiotic U-58,431 (1981-05-12),

13. 4259450 - Antibiotic acanthomycin and process for preparing (1981-03-31),

14. 4107296 - Antibiotic rubradirin C (1978-08-15),

15. 4107295 - Antibiotic rubradirin B and process for preparing the same (1978-08-15),

Title: The Innovative Contributions of Fritz Reusser

Introduction

Fritz Reusser is a notable inventor based in Portage, MI, with a remarkable portfolio of 18 patents. His work has significantly impacted the field of pharmaceuticals, particularly in the treatment of resistant bacterial infections.

Latest Patents

Among his latest patents are the pyrimidine-thioalkyl and alkylether compounds, which have shown promise in medical applications. Notably, he has developed a treatment involving rubradirin for methicillin-resistant staphylococcal infections. This discovery highlights the potential of rubradirin in addressing serious health challenges posed by resistant bacteria.

Career Highlights

Fritz Reusser has had a distinguished career, working with prominent companies such as The Upjohn Company and Pharmacia & Upjohn Company. His contributions to these organizations have been instrumental in advancing pharmaceutical research and development.

Collaborations

Throughout his career, Reusser has collaborated with esteemed colleagues, including Alexander D Argoudelis and Betty R Hannon. These partnerships have fostered innovation and have been vital in the successful development of his patented technologies.

Conclusion

Fritz Reusser's innovative work and dedication to pharmaceutical advancements have made a significant impact in the field. His contributions continue to influence the treatment of bacterial infections, showcasing the importance of innovation in healthcare.